<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>References on</title><link>https://notes.beauhilton.com/reference/</link><description>Recent content in References on</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><atom:link href="https://notes.beauhilton.com/reference/index.xml" rel="self" type="application/rss+xml"/><item><title>Adrenocortical carcinomas and malignant phaeochromocytomas ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up</title><link>https://notes.beauhilton.com/reference/fassnachtAdrenocorticalCarcinomasMalignant2020/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://notes.beauhilton.com/reference/fassnachtAdrenocorticalCarcinomasMalignant2020/</guid><description>[btni:: incidence of paraganglioma and pheochromocytoma] [btn:: 2-8 million/year]
[btni:: incidence of pants] [btn:: 8 million/year]</description></item><item><title>Where and When to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer</title><link>https://notes.beauhilton.com/reference/vermorkenWhereWhenUse2021/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://notes.beauhilton.com/reference/vermorkenWhereWhenUse2021/</guid><description>[[HPV+ OPSCC incidence over time]]
&amp;ldquo;&amp;hellip;overall HPV prevalence in OPSCC is increasing significantly over time:
from 40.</description></item></channel></rss>